<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875169</url>
  </required_header>
  <id_info>
    <org_study_id>RSJ10333</org_study_id>
    <nct_id>NCT04875169</nct_id>
  </id_info>
  <brief_title>Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double Blind and Placebo Controlled Phase 3 Study to Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reistone Biopharma Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reistone Biopharma Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will&#xD;
      enroll approximately 330 subjects aged 12 to 75 years old with moderate to severe atopic&#xD;
      dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of a screening period followed by a placebo-controlled treatment period&#xD;
      and then an extension treatment period and completed after a follow-up period after the&#xD;
      completion of active treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator's Global Assessment (IGA) score of 0/1 at Week 16</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of subjects achieving Investigator's Global Assessment (IGA) score of clear (0) or almost clear (1) and a reduction from baseline of ≥2 points at Week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eczema Area and Severity Index (EASI 75) at Week 16</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of subjects achieving at least a 75% improvement in Eczema Area and Severity Index (EASI 75) from baseline at Week 16.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Worst-Itch Numeric Rating Scale (WI-NRS-4)-4 at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Proportion of subjects achieving an improvement of Worst-Itch Numeric Rating Scale (WI-NRS) ≥4 from baseline at Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst-Itch Numeric Rating Scale (WI-NRS) at Week 1, 4, 8 and 12</measure>
    <time_frame>Week 1, 4, 8 and 12</time_frame>
    <description>Proportion of subjects achieving an improvement of WI-NRS ≥4 from baseline at all scheduled visits during placebo-controlled treatment phase other than Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to WI-NRS response</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Time from baseline to achieve at least 4 points improvement of WI-NRS during placebo-controlled treatment phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EASI 75 at Week 1, 4, 8 and 12</measure>
    <time_frame>Week 1, 4, 8 and 12</time_frame>
    <description>Proportion of subjects achieving EASI 75 at all scheduled visits during placebo-controlled treatment phase except Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA 0/1 at Week 1, 4, 8 and 12</measure>
    <time_frame>Week 1, 4, 8 and 12</time_frame>
    <description>Proportion of subjects achieving IGA0/1 and a reduction from baseline of ≥2 points at all scheduled visits during placebo-controlled treatment phase except Week 16.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>NRS-4 at Week 24, 32, 40, 52 and 56</measure>
    <time_frame>All scheduled visits from Week 24 - 56</time_frame>
    <description>Proportion of subjects achieving an improvement of WI-NRS ≥4 from baseline at all scheduled visits during extension treatment phase.</description>
  </other_outcome>
  <other_outcome>
    <measure>EASI 75 at Week 24, 32, 40, 52 and 56</measure>
    <time_frame>All scheduled visits from Week 16 24 - 56</time_frame>
    <description>Proportion of subjects achieving EASI 75 at all scheduled visits during extension treatment phase.</description>
  </other_outcome>
  <other_outcome>
    <measure>IGA 0/1 at Week 24, 32, 40, 52 and 56</measure>
    <time_frame>All scheduled visits from Week 24 - 56</time_frame>
    <description>Proportion of subjects achieving IGA0/1 and a reduction from baseline of ≥2 points at all scheduled visits during extension treatment phase.</description>
  </other_outcome>
  <other_outcome>
    <measure>EASI 50 and EASI 90 at Week 1, 4, 8, 12, 16, 24, 32, 40, 52 and 56</measure>
    <time_frame>Day 1 to Week 56</time_frame>
    <description>Proportion of subjects with ≥50% EASI improvement from baseline (EASI 50) at all scheduled visits.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of EASI from baseline at Week 1, 4, 8, 12, 16, 24, 32, 40, 52 and 56</measure>
    <time_frame>Day 1 to Week 56</time_frame>
    <description>Change from baseline in the eczema area and severity index (EASI) total score at all scheduled visits. The EASI score ranges from 0.0 to 72.0, can be varied in increments of 0.1, Higher scores indicate greater severity.</description>
  </other_outcome>
  <other_outcome>
    <measure>SCORAD 50, SCORAD 75 and SCORAD 90 at Week 1, 4, 8, 12, 16, 24, 32, 40, 52 and 56</measure>
    <time_frame>Day 1 to Week 56</time_frame>
    <description>SCORing Atopic Dermatitis (SCORAD). Score of 0-103. Higher scores mean more severe. Proportion of subjects achieving a ≥50%, 75% and 90% improvement in SCORAD (SCORAD 50, SCORAD 75 and SCORAD 90) from baseline at all scheduled visits.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of SCORAD from baseline at Week 1, 4, 8, 12, 16, 24, 32, 40, 52 and 56</measure>
    <time_frame>Day 1 to Week 56</time_frame>
    <description>Change from baseline in SCORAD at all scheduled visits</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of BSA from baseline at Week 1, 4, 8, 12, 16, 24, 32, 40, 52 and 56</measure>
    <time_frame>Day 1 to Week 56</time_frame>
    <description>Change from baseline in body surface area (BSA) affected at all scheduled visits</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of IgE from baseline at Week 1, 4, 8, 12, 16, 24, 32, 40, 52 and 56</measure>
    <time_frame>Day 1 to Week 56</time_frame>
    <description>Change from baseline in the level of serum IgE in peripheral blood at all scheduled visits.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of eosinophils from baseline at Week 1, 4, 8, 12, 16, 24, 32, 40, 52 and 56</measure>
    <time_frame>Day 1 to Week 56</time_frame>
    <description>Change from baseline in the level of serum eosinophils in peripheral blood at all scheduled visits.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of dermatology life quality index (DLQI) or Children's DLQI (CDLQI) PROs from baseline at Week 4, 8, 12, 16, 24, 32, 40, 52 and 56</measure>
    <time_frame>Day 1 to Week 56</time_frame>
    <description>Change from baseline in dermatology life quality index (DLQI) or Children's DLQI (CDLQI) score at all scheduled visits. The DLQI CDLQI consists of questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. This is not a scale. There are no minimum or maximum values. The quality index just captures a subjects perception of the impact of skin disease on different aspects of their health-related quality of life over the last week.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of Patient-Oriented Eczema Measure (POEM) from baseline at Week 4, 8, 12, 16, 24, 32, 40, 52 and 56</measure>
    <time_frame>Day 1 to Week 56</time_frame>
    <description>Change from baseline in Patient-Oriented Eczema Measure (POEM) at all scheduled visits. 7-item, patient-administered scale that assesses disease severity in children and adults. Subjects respond to questions about the frequency of 7 symptoms (itching, sleep disturbance, bleeding, weeping/oozing, cracking, flaking, and dryness/roughness) over the last week. Response categories include &quot;No days,&quot; &quot;1-2 days,&quot; &quot;3-4 days,&quot; &quot;5-6 days,&quot; and &quot;Every day&quot; with corresponding scores of 0, 1, 2, 3, and 4, respectively. Scores range from 0-28 with higher total scores indicating greater disease severity.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Core Treatment Active Experimental: SHR0302 Dose#1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Core Treatment Active Experimental: SHR0302 Dose#2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Core Treatment Placebo Comparator: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension Treatment Active Experimental: SHR0302 Dose#1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension Treatment Active Experimental: SHR0302 Dose#2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Core Treatment Active Experimental: SHR0302 Dose#1</intervention_name>
    <description>Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks</description>
    <arm_group_label>Core Treatment Active Experimental: SHR0302 Dose#1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Core Treatment Active Experimental: SHR0302 Dose#2</intervention_name>
    <description>Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks</description>
    <arm_group_label>Core Treatment Active Experimental: SHR0302 Dose#2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Core Treatment Placebo Comparator: Placebo</intervention_name>
    <description>Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks</description>
    <arm_group_label>Core Treatment Placebo Comparator: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extension Treatment Active Experimental: SHR0302 Dose#1</intervention_name>
    <description>Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks</description>
    <arm_group_label>Extension Treatment Active Experimental: SHR0302 Dose#1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extension Treatment Active Experimental: SHR0302 Dose#2</intervention_name>
    <description>Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks</description>
    <arm_group_label>Extension Treatment Active Experimental: SHR0302 Dose#2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects must be at least at ≥12 and ≤75 years of age and body weight&#xD;
             ≥40 kg&#xD;
&#xD;
          2. Subject has a diagnosis of atopic dermatitis for at least 1 year.&#xD;
&#xD;
          3. Meets all of the following disease activity criteria: BSA ≥10% of AD involvement. EASI&#xD;
             ≥16. IGA ≥3. WI-NRS ≥4&#xD;
&#xD;
          4. Subject has a recent history (within 6 months before the screening visit) of&#xD;
             inadequate response or inability to tolerate topical AD treatments (TCS or TCI) or who&#xD;
             have required systemic treatments for control of their disease.&#xD;
&#xD;
          5. Are willing to discontinue certain treatments for eczema (such as systemic and topical&#xD;
             treatments during a washout period).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical history including thrombocytopenia, coagulopathy or platelet dysfunction,&#xD;
             malignancies, current or history of certain infections, lymphoproliferative disorders&#xD;
             and other medical conditions at the discretion of the investigator.&#xD;
&#xD;
          2. Have received certain treatments that are contraindicated.&#xD;
&#xD;
          3. Subject currently has been diagnosed and has active forms of other inflammatory skin&#xD;
             disease (e.g., psoriasis, or lupus erythematosus) that would interfere with the&#xD;
             evaluation of atopic dermatitis or response to treatment.&#xD;
&#xD;
          4. Other active non-AD inflammatory skin diseases or conditions affecting skin&#xD;
&#xD;
          5. Subject with active/severe concomitant disease (s)/symptom(s) that requires&#xD;
             administering of systemic corticosteroids or otherwise interferes with study&#xD;
             participation or requires active frequent monitoring (e.g., unstable chronic asthma).&#xD;
&#xD;
          6. Acute or chronic medical or laboratory abnormality that may increase the risk&#xD;
             associated with study participation.&#xD;
&#xD;
          7. Medical history including thrombocytopenia, coagulopathy or platelet dysfunction,&#xD;
             malignancies, current or history of certain infections, lymphoproliferative disorders&#xD;
             and other medical conditions at the discretion of the investigator.&#xD;
&#xD;
          8. Unwilling to discontinue current AD medications prior to the study or require&#xD;
             treatment with prohibited medications during the study&#xD;
&#xD;
          9. Subject has any malignancies or has a history of malignancies with the exception of&#xD;
             adequately treated or excised non-metastatic basal cell or squamous cell cancer of the&#xD;
             skin, or cervical carcinoma in situ.&#xD;
&#xD;
         10. Pregnant or breastfeeding women, or women of childbearing potential who are unwilling&#xD;
             to use contraception.&#xD;
&#xD;
         11. Subject has a previously received systemic JAK inhibitors&#xD;
&#xD;
         12. Unwilling to discontinue current AD medications prior to the study or require&#xD;
             treatment with prohibited medications during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Imran Ghiasuddin</last_name>
    <phone>8472937866</phone>
    <email>imran.ghiasuddin@reistonebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenfeng Wu</last_name>
    <email>wenfeng.wu@reistonebio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr Chih-ho Hong Medical Inc.</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chih-ho Hong</last_name>
    </contact>
    <investigator>
      <last_name>Chih-ho Hong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Enverus Medical Research</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorne Albrecht</last_name>
    </contact>
    <investigator>
      <last_name>Lorne Albrecht</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wiseman Dermatology Research</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Warni Wiseman</last_name>
    </contact>
    <investigator>
      <last_name>Warni Wiseman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CCA Medical Research</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Adam</last_name>
    </contact>
    <investigator>
      <last_name>David Adam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SKiN Health</name>
      <address>
        <city>Cobourg</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Gooderham</last_name>
    </contact>
    <investigator>
      <last_name>Melinda Gooderham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DermEffects</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Jing Loo</last_name>
    </contact>
    <investigator>
      <last_name>Wei Jing Loo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North York Research Inc.</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Firouzeh Firouzeh</last_name>
    </contact>
    <investigator>
      <last_name>Firouzeh Niakosari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Centre for Dermatology</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mani Raman</last_name>
    </contact>
    <investigator>
      <last_name>Mani Raman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sameh Hanna</last_name>
    </contact>
    <investigator>
      <last_name>Sameh Hanna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Research Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxwell Sauder</last_name>
    </contact>
    <investigator>
      <last_name>Maxwell Sauder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>XLR8 Clinical Research</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daryl Toth</last_name>
    </contact>
    <investigator>
      <last_name>Daryl Toth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique D</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Danielle Brassard</last_name>
    </contact>
    <investigator>
      <last_name>Danielle Brassard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yang sen Yang sen</last_name>
    </contact>
    <investigator>
      <last_name>Yang sen Yang sen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University(Xiamen Branch)</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gao Lujuan</last_name>
    </contact>
    <investigator>
      <last_name>Gao Lujuan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dermatology Hospital of Southern M University</last_name>
    </contact>
    <investigator>
      <last_name>Yang Bin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Han Jiande</last_name>
    </contact>
    <investigator>
      <last_name>Han Jiande</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuhan No.1 Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chen Liu Qing</last_name>
    </contact>
    <investigator>
      <last_name>Chen Liu Qing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Li</last_name>
    </contact>
    <investigator>
      <last_name>Jie Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiao Rong</last_name>
    </contact>
    <investigator>
      <last_name>Xiao Rong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Skin Diseases, Chinese Academy of medical sciences</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yao Xu</last_name>
    </contact>
    <investigator>
      <last_name>Yao Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu province people's hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lu Yan</last_name>
    </contact>
    <investigator>
      <last_name>Lu Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuxi No.2 People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhu Xiao Hong</last_name>
    </contact>
    <investigator>
      <last_name>Zhu Xiao Hong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xu Hui</last_name>
    </contact>
    <investigator>
      <last_name>Xu Hui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial Hospital of Dermatology</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hu Guohong</last_name>
    </contact>
    <investigator>
      <last_name>Hu Guohong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first hospital of jilin university</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Shan Shan</last_name>
    </contact>
    <investigator>
      <last_name>Li Shan Shan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xi 'an Jiaotong</name>
      <address>
        <city>Xian</city>
        <state>Shan XI</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geng Song Mei</last_name>
    </contact>
    <investigator>
      <last_name>Geng song mei Geng song mei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Jingyi</last_name>
    </contact>
    <investigator>
      <last_name>Li Jingyi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Litao A Zhang</last_name>
      <email>zhanglitao@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Litao ZHANG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ji Chao</last_name>
    </contact>
    <investigator>
      <last_name>JiChao JiChao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital Affiliated to Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Yun Yun Ling</last_name>
    </contact>
    <investigator>
      <last_name>Li Yun Ling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first people's hospital of hangzhou</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wu Liming</last_name>
    </contact>
    <investigator>
      <last_name>Wu Liming</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The fourth hospital affiliated to zhejiang university school of medicine</name>
      <address>
        <city>Yiwu</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liu Lunfei</last_name>
    </contact>
    <investigator>
      <last_name>Liu Lunfei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking union medical college hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongzhong Jin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Children's Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MA Lin</last_name>
    </contact>
    <investigator>
      <last_name>Ma Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Capital Institute of Pediatrics</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gao Ying</last_name>
    </contact>
    <investigator>
      <last_name>Gao Ying</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University third hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhang Chun lei</last_name>
    </contact>
    <investigator>
      <last_name>Zhang Chun lei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiangyu Lu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Traditional Chinese medicine Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diao Qing chun</last_name>
    </contact>
    <investigator>
      <last_name>Diao Qing chun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First affiliated hospital of chongqing medical university</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chen Ai Jun</last_name>
    </contact>
    <investigator>
      <last_name>Chen Ai Jun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Southwest Hospital of AMU</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>song zhi qiang</last_name>
    </contact>
    <investigator>
      <last_name>song zhi qiang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang province People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaohua Tao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermatology hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yang-feng Ding</last_name>
    </contact>
    <investigator>
      <last_name>Yang-feng Ding</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gu Chao Ying</last_name>
    </contact>
    <investigator>
      <last_name>Gu Chao Ying</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first hospital of China medical university</name>
      <address>
        <city>Shenyang</city>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinghua M Gao</last_name>
      <email>gaobarry@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 1, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

